Clinical Research Directory
Browse clinical research sites, groups, and studies.
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
Sponsor: Menzies School of Health Research
Summary
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\<30% activity)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-05-17
Completion Date
2028-12-31
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days
Primaquine 1mg/kg/day for 7 days
Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).
8 weekly Primaquine (0.75mg/kg dose).
Locations (4)
Dr Marcus Lacerda
Manaus, Brazil
Arba Minch General Hospital
Arba Minch, Ethiopia
Dr Moses Laman and Dr Brioni Moore
Alexishafen, Madang Province, Papua New Guinea
Papua New Guinea Institute of Medical Research
Port Moresby, Magang, Papua New Guinea